statins, and ticagrelor (Brilinta; 45%) as the preferred P2Y12 inhibitor over clopidogrel (Plavix; 42%) or prasugrel (Effient ...

There was no meaningful protection from major cardiac events after MI, reported investigators of the multinational placebo-controlled trial that is challenging common clinical practice.

At a median follow-up of three years, the composite of cardiovascular death, recurrent MI, stroke, or ischemia driven revascularization was not significantly different between the colchicine and ...

Among the recommendations for future research developed through the Delphi rounds was the optimal dose and frequency of oral colchicine for the treatment of an acute attack. Although the usual ...